Looking at Tango Therapeutics, Inc.'s (NASDAQ:TNGX ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

See our latest analysis for Tango Therapeutics

The Last 12 Months Of Insider Transactions At Tango Therapeutics

The Independent Director Mace Rothenberg made the biggest insider purchase in the last 12 months. That single transaction was for US$74k worth of shares at a price of US$3.78 each. That means that an insider was happy to buy shares at above the current price of US$3.03. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Mace Rothenberg was the only individual insider to buy shares in the last twelve months.

All up, insiders sold more shares in Tango Therapeutics than they bought, over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

I will like Tango Therapeutics better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Insiders At Tango Therapeutics Have Sold Stock Recently

We've seen more insider selling than insider buying at Tango Therapeutics recently. We note insiders cashed in US$143k worth of shares. Meanwhile Independent Director Mace Rothenberg bought US$74k worth , as we said above . Since the selling really does outweigh the buying, we'd say that these transactions may suggest that some insiders feel the shares are not cheap.

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data indicates that Tango Therapeutics insiders own about US$6.2m worth of shares (which is 1.8% of the company). We do generally prefer see higher levels of insider ownership.

So What Does This Data Suggest About Tango Therapeutics Insiders?

The insider sales have outweighed the insider buying, at Tango Therapeutics, in the last three months. Zooming out, the longer term picture doesn't give us much comfort. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. We'd certainly practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Tango Therapeutics. For example - Tango Therapeutics has 2 warning signs we think you should be aware of.

But note: Tango Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.